Table 1.
Characteristics of the breast cancer cohort.
Fig 1.
Correlation between the MammaPrint risk classification and the EP score (left) and EPclin score (right).
Threshold values for EP- and EPclin-based risk classification are indicated as dashed lines.
Table 2.
Correlation between EP/ EPclin score and MammaPrint.
Fig 2.
Correlation of the Ki-67 proliferation indices and MammaPrint (A), EP (B) or EPclin (C) score risk classification (threshold values of Ki-67 are registered as vertical dashed lines. Tumour cells with a Ki-67 proliferation index <15% were scored as negative, 16%-25% as intermediate and >25% as positive).
Fig 3.
A) Initial choice of therapy based on taking only the clinico-pathological parameters tumour size, nodal status and hormone receptor status as well as HER2 status into account B) Actual choice of therapy based on the inclusion of the MammaPrint test result C) Hypothetical choice of therapy based on the inclusion of the EPclin Score test result instead of the MammaPrint results.
Table 3.
Overview of the risk classification of patients with distant metastasis during observation time.